[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fujian Medical University Union Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":617},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,50,0,25,[9,51,75,102,127,154,174,201,231,252,275,299,323,347,370,392,412,434,455,480,507,527,554,574,595],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100644724","ulinastatin-on-systemic-immune-inflammation-in-patients-with-complicated-intra-abdominal-infection-100644724",false,"NCT07672496","Ulinastatin on Systemic Immune-Inflammation in Patients With Complicated Intra-Abdominal Infection","A Single-Center Randomized Controlled Pilot Study on the Effect of Ulinastatin on Systemic Immune and Inflammatory Response in Patients With Complicated Intra-Abdominal Infection","UTI-cIAI","Inclusion Criteria:\n\n1. Able to provide written informed consent voluntarily.\n2. Age ≥ 18 years old, any gender.\n3. Diagnosed with severe complicated intra-abdominal infection (cIAI) within 48 hours, consistent with the 2025 expert consensus for cIAI diagnosis. Diagnosis is confirmed by clinical symptoms (fever, abdominal pain, distension, etc.), abdominal imaging (CT\u002Fultrasound\u002FMRI), intraoperative findings, or positive pathogen culture of abdominal drainage fluid.\n4. Baseline Sequential Organ Failure Assessment (SOFA) score ≥ 2 points.\n\nExclusion Criteria:\n\n1. Severe immune deficiency conditions, including AIDS, prior solid organ or bone marrow transplantation, HIV infection with CD4 count \\\u003C 200 cells\u002Fmm³, long-term high-dose glucocorticoid therapy (prednisone \\> 20 mg\u002Fday), ongoing chemotherapy for malignant tumors, or absolute neutrophil count \\\u003C 1000 cells\u002Fmm³.\n2. Severe irreversible underlying diseases, including chronic renal failure requiring dialysis, Child-Pugh grade C liver disease, liver disease with severe portal hypertension, or acute liver failure.\n3. Patients with active malignant tumors, pregnancy, or severe psychiatric disorders.\n4. American Society of Anesthesiologists (ASA) physical status grade IV or above.\n5. Severe coagulation disorder defined as ISTH-DIC score ≥ 5 points.\n6. Critically ill patients with expected death within 48 hours after admission.\n7. Known allergy to ulinastatin or any ingredients of the study preparation.\n8. Any condition that, in the judgment of the principal investigator, makes the patient inappropriate for trial participation.","ALL","18 Years",{"count":21,"type":22},165,"ESTIMATED","INTERVENTIONAL",[25],"NA","Complicated intra-abdominal infection (cIAI) triggers dysregulated systemic inflammation and immune paralysis leading to high organ failure and death risk. Ulinastatin is a protease inhibitor with anti-inflammatory properties, but its dose-related effects on immune-inflammation of cIAI patients remain unclear. This single-center single-blinded three-arm randomized controlled pilot study enrolls adult cIAI patients (≥18 years, SOFA≥2) at Fujian Medical University Union Hospital. Eligible patients are randomized into low-dose ulinastatin, high-dose ulinastatin and normal saline placebo groups (1:1:1, 5 days intravenous treatment plus standard care), total planned enrollment 165 participants after 10% dropout adjustment. Primary endpoint is Day5 change of Systemic Immune-Inflammation Index (SII); secondary outcomes include serial inflammatory biomarkers, SOFA variation, organ dysfunction, hospitalization duration, 28-day mortality and safety profiles. This pilot aims to clarify ulinastatin's immune-modulating effect and inform future large RCT design.",[28,29,30,31],"Complicated Intra-abdominal Infection (cIAI)","Systemic Inflammatory Response","Sepsis","Immune Dysfunction",[33,34,35,36,37],"immune dysfunction","Complicated intra-abdominal infection","Ulinastatin","SII","inflammation","NOT_YET_RECRUITING","2026-06-26",{"date":41,"type":42},"2026-06-29","ACTUAL",{"date":44,"type":22},"2026-10-30",{"date":46,"type":22},"2028-06-30",{"name":48,"class":49},"Fujian Medical University Union Hospital","OTHER",1,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":18,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":50},"100645144","integrated-digital-and-neurogenic-exosome-biomarkers-for-early-diagnosis-of-parkinsons-disease-development-and-application-100645144","NCT07679256","Integrated Digital and Neurogenic Exosome Biomarkers for Early Diagnosis of Parkinson's Disease: Development and Application","Inclusion Criteria:\n\n* 1\\. Healthy Control Group\n\n  1. No severe mental illness;\n  2. Mini-Mental State Examination (MMSE) score \\>24 points; 2. Prodromal PD Group\n\n  \u003C!-- -->\n\n  1. Meets the diagnostic criteria for rapid eye movement sleep behavior disorder;\n  2. Has no severe mental disorders;\n  3. Mini-Mental State Examination (MMSE) score is greater than 24 points. 3. Early PD Group\n\n  (1) Diagnosed with idiopathic Parkinson's disease based on the MDS clinical diagnostic criteria ; (3) Hoehn-Yahr (H-Y) stage \\\u003C=2.0 during off-medication periods; (4) Mini-Mental State Examination (MMSE) score \\>24 points;\n\nExclusion Criteria:\n\n1. Presence of mental, cognitive, or psychological disorders, unable to sign informed consent;\n2. Presence of other diseases affecting walking distance, such as lower limb joint lesions, spinal lesions, neurological disorders, or severe cardiopulmonary diseases;\n3. Presence of intracranial structural changes, cerebrovascular disease, or other neurological disorders;\n4. Presence of tumors, severe liver or kidney dysfunction (indicators exceeding three times the normal value), or other conditions that significantly impact health;\n5. Claustrophobia or presence of implants affecting MRI scanning.",true,"40 Years","80 Years",{"count":61,"type":22},700,"OBSERVATIONAL","Based on the high-quality Parkinson's disease cohort population and biological sample database in the early stage of the team, multi-dimensional intelligent wearable device technology and machine learning were used to screen and classify digital biomarkers in the prodromal PD cohort, early PD cohort and healthy population cohort. Using peptide nanoprobes, metabolomics and Simoa technology to find the pathological molecular biomarkers of high-purity blood neurogenic exosomes in the prodromal stage of PD cohort, early PD cohort and healthy population cohort, and conduct classification and combination study. The association analysis was used to explore the specific internal relationship between digital biomarkers and neurogenic exosome molecular biomarkers, to explore the potential relationship between the two types of biomarkers, and to further apply machine learning methods to establish a fusion model for early diagnosis of PD including markers related to digital phenotype and pathological molecular mechanism, and to verify it clinically. The research results of this project are expected to bring new strategies for the early diagnosis of PD biomarkers, provide theoretical support for clinical transformation, and have important clinical significance for achieving the goal of early diagnosis and early treatment.",[65],"PARKINSON DISEASE (Disorder)","RECRUITING","2026-06-25",{"date":69,"type":42},"2026-07-01",{"date":71,"type":42},"2024-01-01",{"date":73,"type":22},"2027-12-31",{"name":48,"class":49},{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":96,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100645058","phase-1-a-clinical-study-on-the-safety-and-efficacy-of-wide-band-ultrasound-combined-with-traditional-chinese-medicine-preparations-in-the-prevention-and-treatment-of-keloids-100645058","NCT07679243","A Clinical Study on the Safety and Efficacy of Wide-Band Ultrasound Combined With Traditional Chinese Medicine Preparations in the Prevention and Treatment of Keloids","WBUS +TCM","Inclusion Criteria:\n\nI-1 Multiple keloid lesions (≥2) on the body, requiring surgical excision and revision. The two targeted lesions shall be separated by at least 1 cm and located in the same anatomical region (e.g., abdomen, chest, upper extremity, lower leg, etc.).\n\nI-2 Aged 14 to 60 years. I-3 The targeted keloid lesions have shown no significant spontaneous regression or continuous enlargement within the past 3-6 months,or are accompanied by obvious symptoms such as itching or pain.\n\nI-4 Has fully understood the purpose, protocol, potential benefits, risks, countermeasures, and rights and obligations of the study (including privacy protection and voluntary withdrawal), and is willing to participate and cooperate well.\n\nI-5 Able to understand and sign the informed consent form, and willing to comply with treatment and follow-up.\n\nI-6 No history of allergy to any known components of the selected traditional Chinese medicine (TCM) preparation.\n\nI-7 No prior treatment for the targeted keloid lesions within 6 months before study initiation.\n\nExclusion Criteria:\n\nE-1 Currently participating in other clinical trials.E-2 Active infection or ulceration present in the targeted keloid area.E-3 Refusal to undergo surgery or biopsy for pathological confirmation.E-4 Hypertension, hypotension, or heart disease (including history of myocardial ischemia, coronary heart disease, myocarditis, etc.).E-5 Hepatic or renal insufficiency.E-6 Infectious diseases (including viral hepatitis, syphilis, AIDS, etc.).E-7 Hematological disorders (abnormal coagulation function, anemia, leukemia, polycythemia vera, aplastic anemia, etc.).E-8 Allergic constitution (urticaria, bronchial asthma, history of allergy to more than two drugs or foods).E-9 Respiratory diseases (chronic bronchitis, emphysema, bronchiectasis, pulmonary insufficiency, chronic obstructive pulmonary disease, interstitial pneumonia).E-10 Digestive system diseases (severe gastric and duodenal ulcers, chronic gastroenteritis, chronic pancreatitis).E-11 Urinary system diseases (chronic urinary tract infection, nephritis, nephrotic syndrome).E-12 Endocrine system diseases (hyperthyroidism, diabetes, acromegaly, pituitary diseases, adrenal diseases, etc.).E-13 Organic neurological diseases or mental illnesses (encephalitis, sequelae of brain trauma, epilepsy, schizophrenia, hysteria, depression, severe insomnia, neurasthenia).E-14 Chronic skin diseases (especially infectious, allergic and inflammatory systemic skin diseases, such as generalized eczema, psoriasis, pemphigus, etc.).E-15 Autoimmune diseases and collagen diseases (such as SLE, dermatomyositis, scleroderma, etc.).E-16 History of long-term smoking, alcohol abuse, or drug abuse.E-17 History of malignant tumor within the past 5 years, currently requiring other treatments such as radiotherapy and chemotherapy.E-18 Received blood transfusion or organ transplantation from others within the past 5 years.E-19 Pregnant, lactating, menstruating, or within 1 year after termination of pregnancy.E-20 Other conditions deemed unsuitable for participation in the study by the investigator.","14 Years","60 Years",{"count":85,"type":22},120,[87,88],"PHASE1","PHASE2","The prevention and treatment of patients with multiple keloids throughout the body are extremely challenging. Keloids are highly resistant, refractory, and prone to recurrence, and are thus known as the \"cancer that does not kill\". At present, the main clinical strategy for such patients is staged surgical resection, followed by adjuvant local radiotherapy. When signs of recurrence appear, local injection of triamcinolone acetonide plus 5-fluorouracil (5-Fu) is administered as supplementary treatment. However, these two combination therapies have obvious limitations.\n\nAdjuvant postoperative radiotherapy is associated with a high incidence of local skin adverse reactions, including radiodermatitis and delayed wound healing. Late complications may occur weeks or months after treatment, such as permanent hyperpigmentation and hypopigmentation, skin atrophy, fibrosis, scabbing and desquamation, and intractable ulcers. In addition, radiotherapy is not suitable for some young female patients and children when keloids are located near organs such as the thyroid gland and gonads.\n\nInjection of triamcinolone acetonide plus 5-Fu causes significant pain and requires repeated sessions. Potential risks include local ulceration, hyperpigmentation, telangiectasia, and menstrual irregularities in female patients. Therefore, there is an urgent clinical need for a pathological scar prevention and treatment technique that can rapidly relieve discomfort, promote scar atrophy, cause no secondary injury, carry low risks, have a short recovery period, provide high comfort during treatment, and be applicable to large-area or multiple pathological scars across the body.\n\nOur research team previously observed in clinical practice that wide-band ultrasound (Universal Beauty® Type I Ultrasound Therapeutic Device) combined with traditional Chinese medicine (TCM) preparations can release abnormally accumulated and contracted collagen fibers in scar tissue via ultrasonic energy. Meanwhile, ultrasound promotes the penetration of TCM into scar lesions, exerting effects of infection control, inflammation inhibition, subsidence of redness and swelling, and relief of itching and pain.\n\nCompared with conventional scar therapies, this approach achieves rapid symptom control, no secondary damage, no obvious side effects, a short recovery period, and high treatment comfort. It shows particularly significant advantages for large-area or multiple pathological scars throughout the body that are difficult to treat with traditional methods. Preliminary treatment in a small number of volunteers with multiple keloids has achieved satisfactory outcomes without obvious adverse reactions.\n\nThe purpose of this study is to verify the efficacy and safety of wide-band ultrasound combined with TCM preparation (Chuang Li Fu) in the prevention and treatment of keloids through this clinical trial.",[91],"Keloid",[93,94,95],"keloid","Wide-Band Ultrasound","Traditional Chinese Medicine",{"date":69,"type":42},{"date":98,"type":22},"2026-08-01",{"date":100,"type":22},"2028-10-31",{"name":48,"class":49},{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":12,"sex":108,"minAge":19,"maxAge":59,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":111,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":4},"100644096","early-phase-1-clinical-efficacy-of-human-umbilical-cord-mesenchymal-stem-cell-derived-exosomes-combined-with-sodium-hyaluronate-intravesical-instillation-in-the-treatment-of-radiation-cystitis-100644096","NCT07665619","Clinical Efficacy of Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Combined With Sodium Hyaluronate Intravesical Instillation in the Treatment of Radiation Cystitis","Inclusion Criteria:\n\n* Female participants aged 18-80 years.\n* History of pelvic radiotherapy, with completion of radiotherapy at least 6 months prior to enrollment.\n* Clinically diagnosed with radiation cystitis accompanied by persistent lower urinary tract symptoms, such as urinary frequency, urgency, hematuria, or related symptoms.\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Acute urinary tract infection or active tuberculous cystitis.\n* Bladder tumor or bladder metastasis from other malignant tumors.\n* Severe cardiac, pulmonary, hepatic, or renal dysfunction (e.g., ALT\u002FAST \\>3 times the upper limit of normal or serum creatinine above the upper limit of normal).\n* Pregnant or breastfeeding women.\n* Known allergy to sodium hyaluronate or stem cell-derived products.\n* Participation in another clinical trial within the past 3 months.","FEMALE",{"count":110,"type":22},48,[112],"EARLY_PHASE1","The goal of this clinical trial is to learn whether intravesical instillation of human umbilical cord mesenchymal stem cell-derived exosomes combined with sodium hyaluronate is safe and effective for treating radiation cystitis. Radiation cystitis is a complication that may occur after pelvic radiotherapy. Common symptoms include blood in the urine, frequent urination, urgent urination, and painful urination.\n\nThe main questions this study aims to answer are:\n\nCan human umbilical cord mesenchymal stem cell-derived exosomes combined with sodium hyaluronate improve blood in the urine in participants with radiation cystitis? Can this combined treatment help repair injury to the bladder lining and blood vessels? What discomfort or medical problems may occur during the treatment?\n\nResearchers will compare four treatment approaches: human umbilical cord mesenchymal stem cell-derived exosomes combined with sodium hyaluronate, human umbilical cord mesenchymal stem cell-derived exosomes alone, sodium hyaluronate alone, and normal saline as a control. By comparing these groups, researchers hope to find out whether the combined treatment works better than either treatment alone or the control treatment.\n\nParticipants will:\n\nBe screened to confirm whether they are eligible for the study; Sign an informed consent form and complete baseline assessments; Be randomly assigned to one of four treatment groups; Receive intravesical instillation once a week for 4 weeks; Attend follow-up visits at 1 month, 3 months, and 6 months after treatment; Be assessed for blood in the urine, urinary symptoms, cystoscopy findings, quality of life, and safety.\n\nThis study may help provide a new treatment option for radiation cystitis and further evaluate the safety and early effectiveness of this treatment.",[115],"Radiation Cystitis",[115,117,118],"hUC-MSC-derived exosomes","Sodium hyaluronate","2026-06-18",{"date":121,"type":42},"2026-06-24",{"date":123,"type":22},"2026-06-01",{"date":125,"type":22},"2028-06-01",{"name":48,"class":49},{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":83,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":136,"briefSummary":137,"conditions":138,"keywords":141,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":153},"100642715","haplo-cord-hsct-for-amlmds-100642715","NCT07588360","Haplo-Cord HSCT for AML\u002FMDS","Haploidentical Combined With Cord Blood Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes: A Prospective, Multicenter Clinical Study","Inclusion Criteria:\n\n* Age between 14 and 60 years, with no gender restriction.\n* Intermediate- or high-risk AML in first complete remission (CR1).\n* AML in second or subsequent complete remission (≥ CR2).\n* Relapsed or refractory AML.\n* Low-risk AML meeting any of the following: Failure to achieve a ≥3-log reduction in RUNX1::RUNX1T1 transcript level compared with baseline after 2 consolidation cycles, or loss of major molecular remission (MMR) within 6 months; CBFB::MYH11\u002FABL ratio \\> 0.1% at any time point after 2 consolidation cycles in patients with CBFB::MYH11-rearranged AML; Presence of D816 KIT mutation in patients with CBFB::MYH11-rearranged AML; Flow cytometry-positive MRD at any time point after 2 consolidation cycles in patients with CEBPA double-mutant AML; Persistently positive MRD after chemotherapy in patients with NPM1-mutated AML.\n* Intermediate-2 or high-risk MDS according to the IPSS scoring system.\n* Adequate general health status and ability to tolerate hematopoietic stem cell transplantation.\n* Provision of signed informed consent and willingness to comply with study-required follow-up and examinations.\n\nExclusion Criteria:\n\n* Prior history of other hematopoietic stem cell transplantation.\n* History of ex vivo T-cell-depleted stem cell transplantation.\n* Survival duration of less than 1 month after transplantation.\n* Severe organ dysfunction, including significant impairment of hepatic, renal, cardiac, or pulmonary function.\n* Active severe infection, such as uncontrolled pneumonia, sepsis, or other systemic infections.\n* History of severe hypersensitivity reactions to study medications, including cyclophosphamide or anti-thymocyte globulin (ATG).\n* Presence of severe psychiatric disorders or cognitive impairment that precludes compliance with study treatment and follow-up.\n* Pregnant or lactating women.\n* Concurrent malignancy of other organ system.\n* Any other medical conditions deemed inappropriate for study participation by the treating investigators.",{"count":135,"type":22},82,[25],"This study aims to investigate the clinical efficacy of haploidentical-cord blood hematopoietic stem cell transplantation in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), and to analyze the impact of different engraftment patterns (haploidentical engraftment versus cord blood engraftment) on clinical outcomes. By comparing the efficacy of haploidentical-cord blood transplantation in different subtypes of AML and MDS, this research will explore its unique advantages and comparative effectiveness relative to conventional transplantation strategies, so as to provide new evidence for clinical practice.\n\nSpecific research objectives I. To evaluate the efficacy of haploidentical-cord blood hematopoietic stem cell transplantation for AML and high-risk MDS, including the speed of hematopoietic recovery, immune tolerance, and long-term survival rates.\n\nII. To compare the effects of different engraftment patterns (haploidentical engraftment vs. cord blood engraftment) on quality of life, immune tolerance, early complications, and long-term prognosis.\n\nIII. To identify the clinical advantages and indications of haploidentical-cord blood transplantation through data analysis, and to provide a theoretical basis for clinical decision-making.\n\nNovelty of the Study I. Innovation in Hematopoietic Stem Cell Infusion Schedule The present study employs a sequential infusion strategy: haploidentical stem cells are infused on Day 0, and umbilical cord blood cells are infused on Day +6 after transplantation.In contrast to the conventional approach used at most domestic and international centers (including the uzhou Protocol), in which both stem cell sources are infused simultaneously on Day 0, the current protocol delays cord blood infusion. This design confers potential advantages for immune reconstitution and long-term cord blood engraftment.\n\nII. Unique Myeloablative Conditioning Regimen\n\nThe conditioning regimen used in this study is as follows:\n\nFludarabine 25 mg\u002Fm² for 5 days, Cytarabine 2 mg\u002Fm² for 5 days, intravenous Busulfan 3.2 mg\u002Fkg for 3 days, ATG 5 mg\u002Fm² for 2 days, Melphalan 60 mg\u002Fm² for 2 days, and CTX 50.0 mg\u002Fkg daily for 2 days.\n\n(For patients in complete remission (CR) with negative MRD before transplantation, Fludarabine and Cytarabine are administered for 3 days instead of 5 days.) Distinct from regimens at other centers, our team administers cyclophosphamide within the critical window after haploidentical stem cell infusion but before cord blood infusion, establishing a novel sequential conditioning model. This approach balances myeloablative intensity and immunomodulation, creating a favorable environment for subsequent long-term cord blood engraftment.\n\nIII. Engraftment Outcomes and Clinical Value Preliminary clinical experience demonstrates that haplo-cord sequential transplantation following the FA5Cy2Bu3 conditioning regimen combined with low-dose ATG\u002FPTCY can achieve long-term cord blood engraftment in approximately 50% of patients.\n\nBy comparison, other domestic protocols (e.g., the Suzhou Protocol) rarely result in sustained cord blood engraftment.\n\nAchievement of long-term cord blood engraftment is clinically meaningful for reducing relapse rates, lowering the incidence and severity of graft-versus-host disease (GVHD), and improving patient prognosis. These outcomes represent a key advantage of the present protocol.",[139,140],"MDS (Myelodysplastic Syndrome)","AML (Acute Myeloid Leukemia)",[142,143,144],"Acute Myeloid Leukemia(AML)","Myelodysplastic Syndrome(MDS)","haplo-cord HSCT","2026-06-08",{"date":147,"type":42},"2026-06-10",{"date":149,"type":42},"2025-10-20",{"date":151,"type":22},"2029-06-30",{"name":48,"class":49},4,{"id":155,"slug":156,"hasResults":12,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":160,"targetDuration":162,"studyType":62,"phases":4,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":50},"100639559","a-multimodal-convergent-cohort-of-parkinsons-disease-at-fjmuuh-fjmuuh-pd-natural-history-study-100639559","NCT07588763","A Multimodal Convergent Cohort of Parkinson's Disease at FJMUUH (FJMUUH-PD): Natural History Study","Inclusion Criteria:\n\n* The diagnosis of Parkinson's disease (PD) will be made according to the Chinese Diagnostic Criteria for Parkinson's Disease (2016) issued by the Parkinson's Disease and Movement Disorders Group of the Neurology Branch of the Chinese Medical Association, with confirmation by at least two neurologists. Eligible patients must meet all of the following criteria:\n\nDefinite diagnosis of parkinsonism; No absolute exclusion criteria for PD are present; At least 2 supportive criteria for PD are satisfied; No red flags suggestive of alternative diagnoses are present.\n\nExclusion Criteria:\n\n* Patients meeting any of the following conditions will be excluded from the study:\n\nInability to complete assessments using the Unified Parkinson Disease Rating Scale (UPDRS); Inability to complete assessments using the Mini-Mental State Examination (MMSE); History of recurrent stroke causing stepwise deterioration of parkinsonian symptoms; Diagnosis of secondary parkinsonism or Parkinson-plus syndromes; History of recurrent head trauma or confirmed encephalitis; Presence of severe organ dysfunction; Presence of severe endocrine diseases; Presence of hematological disorders; Presence of autoimmune diseases; Current diagnosis of malignant tumors.",{"count":161,"type":22},3000,"10 Years","Parkinson's disease (PD) is a common neurodegenerative disorder in middle-aged and elderly individuals, with a global incidence of 2.0% among adults aged 65 and over. Its pathogenesis remains unclear, and effective preventive and therapeutic approaches are lacking. PD severely impairs patients' physical and mental health and quality of life, while also imposing a substantial burden on families and society. This study will enroll patients with idiopathic PD diagnosed in the Department of Neurology, Fujian Medical University Union Hospital, from 2026 to 2036 to establish a research cohort. Using a non-interventional design, participants will undergo long-term follow-up through regular clinical visits, scale-based assessments, imaging examinations, and biological specimen testing. Corresponding data will be collected to build a research platform, aiming to clarify the pattern of disease progression and identify early diagnostic biomarkers. All testing methods are safe and reliable and will not pose additional risks to patients.\n\nThis study will be conducted in strict compliance with ethical requirements. Prior to enrollment, patients will be fully informed of the study details and will voluntarily provide written informed consent. To mitigate the risk of privacy disclosure, measures including coded management, data encryption, and access restriction will be implemented throughout the study to protect participants' privacy, safeguard their legitimate rights and interests, avoid additional financial burdens, and ensure the study is conducted in a standardized manner.\n\nI hereby pledge to protect the personal privacy of all study participants and respect their autonomy. The study will be conducted in accordance with the principles of the Declaration of Helsinki and the Ethical Review Measures for Life Sciences and Medical Research Involving Human Subjects.",[165],"Parkinson Disease (PD)","2026-05-09",{"date":168,"type":42},"2026-05-15",{"date":170,"type":22},"2026-04-28",{"date":172,"type":22},"2035-12-31",{"name":48,"class":49},{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":57,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":183,"conditions":184,"keywords":187,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":50},"100638844","biomarkers-in-bone-marrow-supernatant-for-predicting-aml-chemosensitivity-100638844","NCT07587944","Biomarkers in Bone Marrow Supernatant for Predicting AML Chemosensitivity","Bone Marrow Microenvironment Signatures for Predicting AML Prognosis and Resistance","Inclusion Criteria:\n\n1. Clinical diagnosis aligns with the \"Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2023)\";\n2. All patients are experiencing their first onset of the disease and have not received any related chemotherapy prior to the study;\n3. Patients participate in the study accompanied by family members and sign informed consent documents.\n\nExclusion Criteria:\n\n1. Patients with concurrent malignancies requiring treatment;\n2. Presence of infectious diseases, including SARS, viral hepatitis, or HIV\u002F AIDS;\n3. Major surgery performed within the last 21 days;\n4. Performance Status (PS) score \\>3;\n5. Severe liver or kidney dysfunction or serious infection;\n6. Severe psychiatric conditions that impair understanding of the study protocol or voluntary withdrawal.",{"count":182,"type":22},405,"Chemoresistance in acute myeloid leukemia (AML) is closely associated with the bone marrow microenvironment. Elevated levels of IL-6, leptin, fumarate, and other factors within the bone marrow microenvironment have been shown to enhance oxidative phosphorylation or antioxidant capacity in AML cells, thereby inducing chemoresistance. To explore their potential as prognostic biomarkers or therapeutic targets, this study plans to enroll 405 newly diagnosed AML patients meeting the criteria of the Chinese Guidelines for the Diagnosis and Treatment of Adult Acute Myeloid Leukemia (2023 Edition), along with 81 sex- and age-matched healthy controls. By analyzing the levels of IL-6, leptin, fumarate, and other factors in patient bone marrow supernatant, we will evaluate their associations with treatment response (primary endpoints: overall survival \\[OS\\] and overall response rate \\[ORR\\] after one cycle of chemotherapy) and prognosis. Furthermore, patient-derived xenograft (PDX) mouse models established from primary AML cells will be used to validate their roles in chemoresistance, aiming to provide a basis for therapies targeting the bone marrow microenvironment.",[185,186],"AML","Adult",[185,188,189,190,191,192],"Chemosensitivity","Biomarker","Fumarate","Leptin","IL-6","2026-05-08",{"date":195,"type":42},"2026-05-14",{"date":197,"type":42},"2025-12-01",{"date":199,"type":22},"2030-01-01",{"name":48,"class":49},{"id":202,"slug":203,"hasResults":12,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":185,"eligibilityCriteria":207,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":23,"phases":211,"briefSummary":213,"conditions":214,"keywords":218,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":50},"100636146","phase-4-study-of-the-effectiveness-and-safety-of-daunorubicin-idarubicin--silibinin-in-treating-newly-diagnosed-aml-non-m3-100636146","NCT07561892","Study of the Effectiveness and Safety of Daunorubicin \u002FIdarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).","Prospective Randomized Study of the Effectiveness and Safety of Chemotherapy Protocols Containing Daunorubicin \u002FIdarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3)","Inclusion Criteria:\n\n1. Newly diagnosed acute leukemia(non-M3)confirmed according to the 2018 WHO classification criteria for the diagnosis and classification of acute leukemia;\n2. Suitable for standard chemotherapy regimens containing idarubicin\u002Fdaunorubicin;\n3. Patients with an expected survival time of at least 3 months as determined by the investigator;\n4. Voluntarily agree to participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. History of other malignant tumors concurrently or previously diagnosed malignancies not under control;\n2. Participation in other clinical trials within one month prior to screening;\n3. Presence of uncontrolled cerebrovascular diseases, coagulation disorders, connective tissue diseases, or other such conditions;\n4. Other uncontrolled diseases that the investigator considers inappropriate for inclusion;\n5. Patients with psychiatric disorders or other known or suspected inability to fully comply with the study protocol;\n6. Pregnant or breastfeeding women;\n7. History of liver cirrhosis, or current active liver disease or biliary disease;\n8. HIV-positive individuals;\n9. Any other conditions that, in the investigator's judgment, may prevent the subject from completing the study or pose significant risk to the subject.","65 Years",{"count":210,"type":22},100,[212],"PHASE4","Silibinin is the major active component of silymarin, a commonly used hepatoprotective agent. It stabilizes hepatocyte membranes, preserves cellular integrity, and accelerates DNA synthesis in liver cells. Clinically, it is widely used in the treatment of chronic persistent hepatitis, chronic active hepatitis, early-stage liver cirrhosis, and hepatotoxicity. Moreover, it has been reported to inhibit the growth and differentiation of various cancer cells, including hepatocellular carcinoma, prostate cancer, breast cancer, and cervical cancer.\n\nBased on these preclinical findings, we aim to evaluate the efficacy and safety of combining silybinin with the standard first-line idarubicin\u002Fdaunorubicin-based regimen in the treatment of newly diagnosed acute leukemia(non-M3)in a clinical setting.",[215,216,217],"Acute Myeloid Leukemia","Newly Diagnosed","Chemotherapy Effect",[185,219,220,221,222],"newly diagnosed","Silybin","daunorubicin","Idarubicin","2026-04-27",{"date":225,"type":42},"2026-05-01",{"date":227,"type":42},"2022-04-01",{"date":229,"type":22},"2026-12-31",{"name":48,"class":49},{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":185,"eligibilityCriteria":237,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":238,"enrollmentInfo":239,"targetDuration":4,"studyType":23,"phases":241,"briefSummary":242,"conditions":243,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":246,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":50},"100635311","phase-1-efficacy-and-safety-of-autologous-peptide-induced-active-immunity-in-aml-maintenance-therapy-100635311","NCT07551037","Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy","A Randomized, Controlled, Prospective Study on the Efficacy and Safety of Active Immunity Induced by Autologous Peptides for Maintenance Therapy in Acute Myeloid Leukemia (AML)","Inclusion Criteria:\n\n* Newly diagnosed with acute myeloid leukemia (AML) in accordance with the 2018 WHO Classification and Diagnostic Criteria for Acute Leukemias; received 1-2 courses of conventional chemotherapy, achieved remission, and are undergoing routine consolidation therapy.\n* Aged 18 to 70 years.\n* Receiving a maintenance therapy regimen without hormonal agents.\n* Leukocyte and lymphocyte counts have basically returned to the normal range.\n* Patients judged by the investigator to have an expected survival of at least 12 months after achieving remission.\n* Patients who voluntarily participate in this study and sign the informed consent form.\n\nExclusion Criteria：\n\n* Patients who still require hormonal maintenance therapy after achieving remission.\n* Patients with a concomitant history of other malignant tumors or a history of uncontrolled malignant tumors.\n* Having participated in other clinical trials within 1 month prior to screening.\n* Complicated with uncontrolled cerebrovascular diseases, coagulation disorders, connective tissue diseases and other similar conditions.\n* Having other uncontrolled diseases that the investigator deems unfit for enrollment.\n* Patients with psychiatric disorders or those known\u002Fsuspected to be unable to fully comply with the study protocol.\n* Pregnant or lactating women.\n* HIV-infected individuals.\n* Other conditions that the investigator deems may prevent the subject from completing the study or pose a significant safety risk to the subject.\n\nWithdrawal Criteria：\n\n* Judged by the investigator to be in the best interest of the subject.\n* Disease progression or initiation of other anti-leukemia therapy.\n* The subject requests to withdraw from the study for any reason at any time.\n* Lost to follow-up.\n* Death.\n* Occurrence of severe chemotherapy-induced toxic reactions, or chemotherapy delay of more than 4 weeks due to adverse reactions.\n* Cardiac toxicity: Left Ventricular Ejection Fraction (LVEF) ≤ 50% or a decrease of \\> 10%; or QTc prolongation meeting the following criteria: ① QTc \\> 500 ms; ② QTc \\> 530 ms in patients with bundle branch block.\n* Hepatic toxicity: Persistent elevation of alanine transaminase (ALT) and\u002For aspartate transaminase (AST) to more than 2 times the upper limit of normal (ULN), with no response to hepatoprotective treatment.","70 Years",{"count":240,"type":22},90,[87],"Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While approximately 70% of patients achieve complete remission (CR) with induction chemotherapy, traditional consolidation therapy (predominantly high-dose cytarabine) has a persistently high recurrence rate - nearly 30% at 1 year for low-risk groups and 80% for high-risk groups - with a long-term survival rate \\\u003C40%. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) improves survival but is limited by donor matching and patient tolerance, resulting in a transplantation rate \\\u003C20%. Clinically, there is an urgent need for a well-tolerated, low hepatotoxic\u002Fnephrotoxic maintenance regimen effective for preventing recurrence.\n\nTumor immunotherapy is a major breakthrough, and neoantigen-based personalized vaccines are a key anti-recurrence direction due to their strong tumor specificity and ability to induce long-term immune memory. However, existing neoantigen vaccines rely on NGS sequencing and bioinformatics for epitope screening, suffering from long development cycles, high costs, proneness to missing cancer-causing mutations, and poor clinical feasibility, hindering widespread use. This study adopts a patented Sino-US innovative technology: in vitro induction of patients' own AML cells to obtain a complete set of tumor antigen peptides for personalized vaccine preparation, circumventing traditional bottlenecks to achieve \"full antigen coverage\" personalized active immunity.\n\nThis study has significant clinical and scientific value: (1) It is the first application of this patented technology in AML maintenance therapy, filling domestic and international research gaps and providing a novel treatment option; (2) Using a randomized controlled design, it compares the efficacy of immunotherapy administered during vs. after consolidation chemotherapy to identify the optimal treatment mode; (3) It screens reliable anti-leukemia immunity monitoring methods and time points, offering evidence-based support for efficacy evaluation and prognostic prediction; (4) It verifies the treatment's safety, laying a foundation for developing low-toxic, high-efficacy AML maintenance regimens, ultimately improving patients' long-term survival and advancing precision immunotherapy for AML.",[215,244,245],"Personalized Active Immunotherapy","Maintenance Therapy",{"date":225,"type":42},{"date":248,"type":42},"2024-09-01",{"date":250,"type":22},"2026-09-01",{"name":48,"class":49},{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":12,"sex":259,"minAge":19,"maxAge":260,"enrollmentInfo":261,"targetDuration":4,"studyType":23,"phases":263,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":50},"100627157","rezvilutamide-for-high-risk-prostate-cancer-after-surgery-100627157","NCT07444983","Rezvilutamide for High-Risk Prostate Cancer After Surgery","An Exploratory Clinical Study of Rezvilutamide as Adjuvant Therapy for High-Risk Patients After Radical Prostatectomy","Inclusion Criteria\n\nSubjects must meet all of the following criteria to be eligible for entry into this study:\n\nAge ≥ 18 years.\n\nHistologically confirmed adenocarcinoma of the prostate following radical prostatectomy.\n\nEvaluated by the investigator as requiring pharmacological treatment.\n\nECOG Performance Status of 0 or 1.\n\nPreoperative imaging ruled out metastatic disease.\n\nMust meet at least one of the following postoperative high-risk factors:\n\nPositive surgical margins;\n\nPathological stage pT3-pT4;\n\nLymph node metastasis;\n\nPreoperative PSA ≥ 20 ng\u002Fml.\n\nUnwilling to receive postoperative radiotherapy.\n\nPSA \\\u003C 0.1 ng\u002Fml during the screening period.\n\nCapable of understanding and voluntarily signing the Informed Consent Form (ICF).\n\nExclusion Criteria\n\nPatients meeting any of the following criteria will be excluded from the study:\n\nPostoperative pathology contains non-adenocarcinoma components, such as neuroendocrine differentiation or small cell features.\n\nKnown or suspected hypersensitivity to Rezvilutamide or any of its excipients.\n\nFactors affecting drug administration or absorption, such as inability to swallow, chronic diarrhea, or intestinal obstruction.\n\nHistory of seizures or presence of conditions predisposing to seizures within 12 months prior to screening (including history of transient ischemic attack, stroke, or traumatic brain injury with loss of consciousness requiring hospitalization).\n\nActive cardiac disease within 6 months prior to screening, including: severe\u002Funstable angina, myocardial infarction, symptomatic congestive heart failure, and ventricular arrhythmias requiring medical treatment.\n\nHistory of other malignancies within 3 years prior to screening (except for completely remitted carcinoma in situ or malignancies judged by the investigator to be slow-progressing).\n\nActive HBV or HCV infection (HBV DNA ≥ 10\\^4 copies\u002FmL, HCV RNA ≥ 10\\^3 copies\u002FmL).\n\nHistory of immunodeficiency (including positive HIV test, other acquired or congenital immunodeficiency diseases) or history of organ transplantation.\n\nMale subjects with female partners of childbearing potential who refuse surgical sterilization or refuse to use effective contraception during the study period.\n\nAny other condition which, in the opinion of the investigator, may interfere with the conduct of the study, compromise protocol compliance, or pose an unacceptable risk to the subject.","MALE","95 Years",{"count":262,"type":22},33,[25],"The goal of this clinical trial is to learn if Rezvilutamide works to treat high-risk prostate cancer in patients who have recently undergone surgery (radical prostatectomy). It will also learn about the safety of Rezvilutamide. The main questions it aims to answer are:\n\nDoes Rezvilutamide, when used as an add-on treatment after surgery, lower the risk of the cancer returning (biochemical recurrence) within 3 years? What is the 36-month metastasis-free survival (MFS) rate for patients receiving this treatment? What is the safety profile of Rezvilutamide combined with ADT, specifically regarding the types, grades, and incidence of Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Drug Reactions (ADRs), Adverse Events of Special Interest (AESIs), and rare adverse events? What are the exploratory findings regarding the status of immune cells after using Rezvilutamide?\n\nResearchers will evaluate the combination of Rezvilutamide and hormone therapy (ADT) to see if it helps keep patients cancer-free.\n\nParticipants will:\n\nTake Rezvilutamide: 240 mg once daily, taken orally before or after breakfast. Each cycle is 28 days, for up to 24 cycles. Treatment continues unless biochemical recurrence, disease progression, intolerable toxicity occurs, or the participant withdraws consent, as determined by the investigator.\n\nReceive Androgen Deprivation Therapy (ADT): Leuprorelin 3.75mg via subcutaneous injection, once every 28 days for a total of 12 cycles.",[266],"Prostate Cancer (Adenocarcinoma)","2026-03-02",{"date":269,"type":42},"2026-03-03",{"date":271,"type":22},"2026-02-11",{"date":273,"type":22},"2029-07-11",{"name":48,"class":49},{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":282,"enrollmentInfo":283,"targetDuration":4,"studyType":23,"phases":285,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":297,"leadSponsor":298,"locationsCount":50},"100624221","phase-3-the-value-of-near-infrared-fluorescence-imaging-in-the-protection-of-the-recurrent-laryngeal-nerve-during-minimally-invasive-esophagectomy-100624221","NCT07406815","The Value of Near-Infrared Fluorescence Imaging in the Protection of the Recurrent Laryngeal Nerve During Minimally Invasive Esophagectomy","The Value of Near-Infrared Fluorescence Imaging in the Protection of the Recurrent Laryngeal Nerve During Minimally Invasive Esophagectomy：A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18 and 75 years at the time of diagnosis (excluding 18 and 75);\n* Preoperative biopsy pathology confirming esophageal cancer;\n* Undergoing elective thoracoscopic esophageal cancer radical surgery with intraoperative anastomosis;\n* Tolerable heart, lung, liver, and kidney function for surgery;\n* Patients and their families are able to understand and willing to participate in this clinical study, and have signed an informed consent form.\n\nExclusion Criteria:\n\n* Allergy to ICG or iodine;\n* History of neck or thoracic surgery;\n* Patients requiring emergency surgery;\n* Tumors involving adjacent organs necessitating combined organ resection;\n* Patients with tumor recurrence or distant metastasis;\n* Participation in or having participated in other clinical trials within 4 weeks prior to selection;\n* History of severe mental illness;\n* Pregnant or lactating women;\n* Patients with other conditions deemed unsuitable for participation by the investigator;\n* Intraoperative conversion to open thoracotomy.\n* Patients who, after assessment or intraoperative exploration, cannot undergo the planned surgery;\n* Patients who voluntarily withdraw from the study;\n* Patients with concomitant non-neoplastic conditions that prevent them from continuing with the study protocol;\n* Patients who, after enrollment in the study, are unable to complete it due to other reasons.","75 Years",{"count":284,"type":22},144,[286],"PHASE3","The goal of this clinical trial is to learn whether the application of indocyanine green near-infrared imaging system can accurately locate the recurrent laryngeal nerve (RLN) during lymph node dissection in esophageal cancer radical surgery, thereby reducing the risk of RLN injury. The main questions it aims to answer are:\n\n1. Can preoperative intravenous administration of indocyanine green enable visualization of the RLN;\n2. Does performing RLN dissection guided by near-infrared imaging system reduce the probability of RLN injury, leading to better clearance of RLN lymph nodes and improved RLN protection rates? Researchers will compare whether indocyanine green was intravenously administered preoperatively to assess intraoperative RLN visualization. Participants in the study group will receive intravenous indocyanine green at a dose of 5mg\u002Fkg 24 hours before surgery. All patients will be monitored for RLN injury-related complications postoperatively, and RLN injury status will be objectively assessed via laryngoscopy one week post-operation.",[289,290,291,292],"Esophageal Cancer","Recurrent Laryngeal Nerve","ICG (Indocyanine Green)","Lymph Node Dissection","2026-02-05",{"date":295,"type":42},"2026-02-12",{"date":123,"type":22},{"date":125,"type":22},{"name":48,"class":49},{"id":300,"slug":301,"hasResults":12,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":306,"enrollmentInfo":307,"targetDuration":4,"studyType":23,"phases":309,"briefSummary":310,"conditions":311,"keywords":314,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":4},"100622920","percutaneous-robotic-navigation-microwave-ablation-versus-ct-guided-microwave-ablation-in-the-treatment-of-pulmonary-nodules-with-ground-glass-opacity-100622920","NCT07389889","Percutaneous Robotic Navigation Microwave Ablation Versus CT-guided Microwave Ablation in the Treatment of Pulmonary Nodules With Ground-glass Opacity","Percutaneous Robotic Navigation Microwave Ablation Versus CT-guided Microwave Ablation in the Treatment of Pulmonary Nodules With Ground-glass Opacity: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged 18 to 85 years\n2. Nodules measuring 3-30mm with ground-glass opacities constituting ≥75% of the lesion\n3. Preoperative clinical evaluation confirming no hilar or mediastinal lymph node metastasis and no distant metastasis\n4. Patients diagnosed as stage IA primary peripheral lung cancer according to the UICC 8th TNM staging system, and with one of the following conditions:\n\n   (i) cannot undergo surgical resection due to poor cardiopulmonary function or advanced age (ii) refusing or unwilling to undergo surgical resection (iii) with newly developed or residual pulmonary nodules after early-stage primary lung cancer surgery (iv) with unilateral lung disease who cannot undergo unilateral surgical resection (v)with multiple primary lung cancers unsuitable for surgical resection\n5. Preoperative ECOG physical status score is 0\u002F1\n6. ASA score is I-III\n7. Patients voluntarily participate in this study and sign the informed consent form\n\nExclusion Criteria:\n\n1. Smoking cessation duration \\\u003C2 weeks\n2. Lesions adjacent to pulmonary artery-vein main trunks\n3. Lesions near the hilum or adjacent to lobar bronchi\n4. Pregnancy or lactation status\n5. Severe mental disorders\n6. History of other malignancies within 5 years\n7. Unstable angina or myocardial infarction within 6 months with coronary angiography showing severe stenosis of major coronary branches\n8. Cerebral infarction or hemorrhage within 6 months\n9. Continuous systemic corticosteroid therapy within 1 month\n10. Patients or their authorized persons who do not wish to comply with the study protocol\n11. Patients with other investigator-assessed ineligibility for the trial","85 Years",{"count":308,"type":22},116,[25],"1. To compare the precision of robot-guided microwave ablation and CT-guided microwave ablation in the treatment of ground-glass nodules.\n2. To evaluate the safety of robot-assisted microwave ablation and CT-guided microwave ablation in the treatment of ground-glass nodules.\n3. Explore the application potential of robot navigation microwave ablation technology in the treatment of pulmonary nodules.",[312,313],"Pulmonary Nodules","Ground-glass Opacity",[315],"ggo","2026-02-03",{"date":293,"type":42},{"date":319,"type":22},"2026-02-01",{"date":321,"type":22},"2029-02-01",{"name":48,"class":49},{"id":324,"slug":325,"hasResults":12,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":12,"sex":259,"minAge":19,"maxAge":83,"enrollmentInfo":330,"targetDuration":4,"studyType":23,"phases":332,"briefSummary":333,"conditions":334,"keywords":336,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":50},"100621625","umbilical-cord-mesenchymal-stem-cell-derived-exosomes-in-the-treatment-of-androgenic-alopecia-100621625","NCT07373054","Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Androgenic Alopecia","Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Androgenic Alopecia: A Prospective, Randomized, Controlled Clinical Trial","Inclusion Criteria:\n\n* Male, aged 18 to 60 years (inclusive), in good general health.\n* Clinical diagnosis of androgenetic alopecia (AGA) according to the 2023 Chinese Clinical Practice Guideline: Diagnosis and Treatment of Androgenetic Alopecia, with a disease duration of less than 5 years and a Hamilton-Norwood scale classification of stage II to IV at the screening visit.\n* Able to fully understand the study's content, procedures, potential benefits, and risks, and willing to provide written informed consent prior to any study-specific procedures.\n* Agrees to comply with the study protocol and refrain from using any other treatments for alopecia for the duration of the study.\n\nExclusion Criteria:\n\n* Unwilling or unable to provide written informed consent.\n* History of any malignancy within the past 5 years (except for adequately treated non-scalp basal cell carcinoma or squamous cell carcinoma in situ).\n* Hypotension (blood pressure \\\u003C 90\u002F60 mmHg) documented within 1 month prior to screening, or uncontrolled hypertension within 3 months prior to screening (defined as failure to achieve a target of \\\u003C 140\u002F90 mmHg while on a stable regimen of at least two antihypertensive medications).\n* Known history of any systemic disease that may affect hair growth or confound study assessments (e.g., HIV infection, connective tissue disease, inflammatory bowel disease, hypothyroidism, iron deficiency anemia, malnutrition, syphilis).\n* Known history of other forms of non-androgenetic alopecia (e.g., diffuse alopecia, alopecia areata, cicatricial alopecia).\n* History of major organ dysfunction, significant autoimmune disease, or immunodeficiency.\n* Known coagulation disorders, current use of anticoagulant or antiplatelet therapy (except low-dose aspirin), thrombophilia, or inherited bleeding disorders.\n* Treatment with chemotherapy, cytotoxic drugs, scalp radiation, or laser\u002Fsurgical hair restoration within 12 months prior to screening.\n* History of hair transplantation, or need for long-term use of wigs, hairpieces, or hair bonding agents during the trial.\n* History of severe or multiple drug allergies, atopy, known allergy to local anesthetics, or planned desensitization therapy during the study period.\n* Presence of any active dermatological condition in the target scalp area that could interfere with evaluation (e.g., infection, seborrheic dermatitis, psoriasis, eczema, folliculitis, open wounds, scars, or atrophy).\n* Participation in another interventional clinical trial within 4 weeks prior to screening (except for non-interventional studies or participants who only signed the informed consent form without receiving any investigational product).\n* Any other medical or psychiatric condition that, in the judgment of the investigator, would compromise the subject's safety, compliance, or suitability for study participation.",{"count":331,"type":22},18,[25],"Androgenic Alopecia(AGA) is a highly prevalent condition for which existing pharmacological and surgical interventions present limitations and side effects, creating a clinical need for safer and more effective therapies. In response, human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-Exos) have emerged as a cell-free therapeutic strategy. Characterized by their rich bioactive components, absence of tumorigenic risk, and high safety profile, hUCMSC-Exos represent a promising approach for hair regeneration. This study aims to evaluate the safety and efficacy of hUCMSC-Exos combined with automated microneedle delivery for treating AGA. By utilizing innovative lyophilization technology to maintain exosomal bioactivity and employing precision microneedle systems for enhanced delivery, this research seeks to provide a new generation solution for androgenic alopecia treatment.",[335],"Androgenic Alopecia",[335,337,338],"stem cell","exosome","2026-01-28",{"date":341,"type":42},"2026-01-30",{"date":343,"type":42},"2025-11-06",{"date":345,"type":22},"2027-05-01",{"name":48,"class":49},{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":12,"sex":18,"minAge":354,"maxAge":355,"enrollmentInfo":356,"targetDuration":4,"studyType":23,"phases":358,"briefSummary":359,"conditions":360,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":50},"100617864","efficacy-and-safety-of-transcranial-magnetic-stimulation-in-treatment-of-alzheimers-disease-100617864","NCT07324161","Efficacy and Safety of Transcranial Magnetic Stimulation in Treatment of Alzheimer's Disease","Efficacy and Safety of Repetitive Transcranial Magnetic Stimulation in the Treatment of Alzheimer's Disease and Exploration of Glymphatic Mechanisms","Inclusion Criteria:\n\n* Meets the 2018 NIA-AA diagnostic criteria for Alzheimer's disease (AD)\n* Meets DSM-5 diagnostic criteria\n* Mild to moderate disease severity (CDR Global Score 1 to 2)\n* Evidence of AD pathology: positive amyloid PET OR positive cerebrospinal fluid (CSF) AD biomarkers OR positive plasma AD biomarkers\n\nExclusion Criteria:\n\n* Contraindications to rTMS treatment\n* Severe complications or immune diseases\n* Unable to cooperate with study procedures\n* History of epilepsy","50 Years","90 Years",{"count":357,"type":22},66,[25],"This study is grounded in the regulatory mechanisms of the glymphatic system and applies repetitive transcranial magnetic stimulation (rTMS) to the treatment of Alzheimer's disease (AD). The clinical efficacy and safety of rTMS will be systematically evaluated. Furthermore, transcranial magnetic stimulation-evoked potentials (TMS-EEG) and functional near-infrared spectroscopy (fNIRS) will be employed to investigate, from the perspectives of synaptic plasticity and neurovascular coupling, the mechanisms by which rTMS influences glymphatic function. Collectively, this work aims to provide new insights into both the therapeutic effectiveness and the underlying mechanisms of rTMS in AD.",[361],"Alzheimer s Disease","2026-01-13",{"date":364,"type":42},"2026-01-14",{"date":366,"type":42},"2025-04-16",{"date":368,"type":22},"2029-04-30",{"name":48,"class":49},{"id":371,"slug":372,"hasResults":12,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":282,"enrollmentInfo":377,"targetDuration":4,"studyType":23,"phases":378,"briefSummary":379,"conditions":380,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":50},"100616255","phase-3-the-value-of-indocyanine-green-guided-near-infrared-fluorescence-technology-in-tracing-sentinel-lymph-nodes-during-esophagectomy-100616255","NCT07303231","The Value of Indocyanine Green-guided Near-infrared Fluorescence Technology in Tracing Sentinel Lymph Nodes During Esophagectomy","The Value of Indocyanine Green-guided Near-infrared Fluorescence Technology in Tracing Sentinel Lymph Nodes During Esophagectomy: A Multicenter Prospective Cohort Study","Inclusion Criteria:\n\n1. Age and gender: 18-75 years old, male and female unlimited;\n2. Preoperative biopsy was pathologically diagnosed as esophageal squamous cell carcinoma;\n3. Preoperative combination with neoadjuvant chemoradiotherapy;\n4. Surgical resection of esophageal carcinoma under endoscopic selection and intraoperative anastomosis;\n5. Heart, lung, liver and kidney functions can tolerate operation;\n6. Patients and their family members can understand and are willing to participate in this clinical study and sign the informed consent.\n\nExclusion Criteria:\n\n1. Allergic to ICG or iodine;\n2. Patients with a history of chest surgery or thoracic lymph node dissection;\n3. Patients needing emergency surgery;\n4. Patients whose tumors involve neighboring organs and need to be removed by combining organs;\n5. Patients with tumor recurrence or distant metastasis;\n6. Patients who had participated in or were participating in other clinical trials within the previous 4 weeks were included;\n7. A history of serious mental illness;\n8. Pregnant or lactating women;\n9. Patients with other conditions considered by the researcher should not participate in the study.",{"count":284,"type":22},[286],"Sentinel lymph nodes, as the primary site of tumor metastasis, play a pivotal role in assessing patient prognosis and planning subsequent treatment strategies. The investigators plan to conduct a multicenter, prospective cohort study to evaluate the effectiveness of indocyanine green (ICG)-guided near-infrared imaging in tracing sentinel lymph node during esophageal squamous cell carcinoma (ESCC) surgery, compared with the gold standard of complete lymph node dissection (CLND), in detecting metastatic disease. This study aims to address the following core questions:\n\n1. In ESCC patients undergoing surgery, can sentinel lymph node biopsy reduce unnecessary lymph node dissection?\n2. In ESCC patients undergoing surgery, can reducing lymph node dissection decrease postoperative complications such as chylothorax and weakened immunity? During the study, ICG will be injected around the tumor under intraoperative gastroscopy guidance, followed by tracking of fluorescent lymph nodes using a thoracoscopic near-infrared camera. Professional thoracic surgeons will group and mark these lymph nodes for intraoperative frozen pathology. Subsequent CLND and routine postoperative pathology will be performed. This study will collect patients' clinical information, ICG imaging results, pathological examination results, and other data for statistical analysis to assess the sensitivity and negative predictive value (NPV) of the ICG imaging system. If the study results support the effectiveness of the ICG imaging system, it has the potential to become an important tool for sentinel lymph node localization and biopsy in future ESCC surgeries, helping to reduce unnecessary lymph node resection and improve surgical efficiency and safety.\n\nParticipants will:\n\n1. Undergo minimally invasive ESCC surgery within 2 weeks of enrollment, including the 14th day.\n2. Receive ICG injection around the tumor under intraoperative gastroscopy guidance during surgery.\n3. Have perioperative, postoperative pathology, and complication information recorded.\n4. Undergo standardized follow-up after surgery.",[289,381,382,383],"Sentinel Lymph Node","Lymphadenectomy","Indocyanine Green","2025-12-11",{"date":386,"type":42},"2025-12-24",{"date":388,"type":22},"2026-01-01",{"date":390,"type":22},"2028-02-01",{"name":48,"class":49},{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":12,"sex":259,"minAge":354,"maxAge":260,"enrollmentInfo":399,"targetDuration":4,"studyType":23,"phases":401,"briefSummary":402,"conditions":403,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":50},"100515958","personalized-optimization-of-systematic-prostate-biopsy-100515958","NCT05998278","Personalized Optimization of Systematic Prostate Biopsy","Diagnostic Performance of a Individualized Reduced-Core Biopsy Strategy in Prostate Cancer: A Prospective, Randomized Controlled Study","Inclusion Criteria:\n\n1. Patients with lesions found on rectal examination with any PSA value;\n2. Patients with abnormal lesions found on imaging with any PSA value;\n3. PSA \\>10.0 ng.ml-1;\n4. Patients with PSA of 4.0-10.0 ng.ml-1 and fPSA\u002FtPSA \\\u003C 0.16; (5 ) mpMRI was performed prior to biopsy and Prostate Imaging Reporting and Data System (PI-RADS V2.1) assessment category ≥3\n\n(6) Willing to truthfully fill in the subject survey scale; (7) Willing to undergo follow-up; (8) The patient himself or his authorized immediate family member has signed the informed consent for clinical trial.\n\nExclusion Criteria:\n\n1. previous biopsy cases;\n2. Patients who have undergone prostate-related surgery, radiotherapy, or anti-androgen therapy;\n3. Patients whopresented with severe hemorrhoids or rectal stenosis, rendering them intolerant to transrectal ultrasound\n4. clotting disordersPatients with severe systemic diseases, such as cardiovascular and cerebrovascular disorders, are not appropriate candidates for surgical intervention.\n5. unable to follow the plan.",{"count":400,"type":22},330,[25],"Targeted biopsy combined systematic biopsy is the gold standard for diagnosis of prostate cancer. Excessive cores in systematic biopsy increases the risk of puncture trauma， bleeding and infection. On the basis of establishing a model with DRS stratification to reduce the cores of systematic biopsy, we propose the (12 cores -x) model innovatively. We hope that through this prospective study to verify the efficacy of the model and provide patients with a new biopsy model with high accuracy and fewer complications.\n\nIn this study， patients with suspected prostate cancer were randomly divided into two groups. Experimental group received targeted biopsy combined personalized systematic biopsy, and the control group received systematic biopsy .The differences of the detection rate of Prostate cancer between the two groups were compared.",[404],"Prostate Adenocarcinoma",{"date":406,"type":42},"2025-12-18",{"date":408,"type":42},"2023-08-23",{"date":410,"type":22},"2025-12-30",{"name":48,"class":49},{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":418,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":306,"enrollmentInfo":420,"targetDuration":4,"studyType":23,"phases":421,"briefSummary":422,"conditions":423,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":433},"100615753","phase-2-neoadjuvant-zanidatamab--tislelizumab--chemotherapy-for-selective-bladder-preservation-in-her2-positive-mibc-100615753","NCT07296705","Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC","Selective Bladder Preservation After Neoadjuvant Zanidatamab Combined With Tislelizumab and Chemotherapy in Patients With HER2-Positive Muscle-Invasive Bladder Cancer: A Multicenter Study","HARBOR","Inclusion Criteria:\n\n1. Willing to participate, able to provide written informed consent, and able to understand and comply with study requirements and the assessment schedule.\n2. Age 18 to 85 years on the date of informed consent.\n3. Residual disease after TURBT; histologically confirmed urothelial carcinoma of the bladder staged cT2-T4aN0-1M0 per AJCC 8th edition by histology and imaging. For mixed histology, urothelial carcinoma must be predominant (≥50%).\n4. Availability of TURBT tumor tissue and corresponding pathology report; either fresh surgical tissue or unstained slides may be submitted.\n5. HER2-positive: IHC 2+ or 3+.\n6. No prior anti-HER2-directed therapy (including but not limited to HER2 antibodies, HER2-targeting ADCs, or HER2-targeted TKIs) and no prior PD-(L)1 therapy.\n7. ECOG performance status 0-2.\n8. Adequate organ function based on screening labs obtained ≤14 days before enrollment:\n\n   a. For the following counts, no growth-factor support within 14 days prior to sample collection: i. Absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL ii. Platelets ≥ 100 × 10\\^9\u002FL iii. Hemoglobin ≥ 90 g\u002FL b. INR or aPTT ≤ 1.5 × upper limit of normal (ULN) c. Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN for Gilbert syndrome or isolated indirect hyperbilirubinemia) d. AST, ALT, and alkaline phosphatase ≤ 2.5 × ULN\n9. Women of childbearing potential must have a negative urine or serum pregnancy test within ≤7 days before enrollment and agree to use highly effective contraception during the study and for ≥120 days after the last dose of zanidatamab, tislelizumab, or chemotherapy (whichever occurs later).\n10. Non-sterilized men must agree to use highly effective contraception during the study and for ≥120 days after the last dose of zanidatamab, tislelizumab, or chemotherapy (whichever occurs later).\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women.\n2. Uncontrolled infection requiring systemic therapy.\n3. Diagnosis of another malignancy within the past 5 years.\n4. Major surgery or significant trauma within 28 days prior to enrollment (placement of a vascular access device and TURBT are not considered major surgery).\n5. Prior radiotherapy to the bladder for bladder cancer.\n6. Active autoimmune disease requiring systemic treatment that, in the investigator's judgment, would affect study therapy.\n7. Any of the following cardiovascular criteria:\n\n   1. Cardiac chest pain within ≤28 days before first study dose, defined as moderate pain that limits activities of daily living.\n   2. Symptomatic pulmonary embolism within ≤28 days before first study dose.\n   3. Any acute myocardial infarction within ≤6 months before first study dose.\n   4. Any history of heart failure of New York Heart Association (NYHA) Class III or IV within ≤6 months before first study dose.\n   5. Any ventricular arrhythmia of severity ≥ Grade 2 within ≤6 months before first study dose.\n   6. Any cerebrovascular accident within ≤6 months before first study dose.\n   7. Corrected QT interval (QTc by Fridericia): ≥470 msec for women or ≥450 msec for men.\n\n   i. Note: If the initial ECG shows QTc \\>450 msec (men) or \\>470 msec (women), a follow-up ECG should be performed to confirm.\n\n   h) Left ventricular ejection fraction (LVEF) ≤50% by multigated acquisition (MUGA) scan or echocardiography (ECHO). The same modality used at baseline must be used for follow-up assessments.\n8. History of acute myocardial infarction or ischemic stroke within 6 months.\n9. Human immunodeficiency virus (HIV) infection (i.e., positive antibodies to HIV-1\u002F2), active syphilis infection, or active tuberculosis infection.\n10. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.\n11. History of interstitial lung disease, non-infectious pneumonitis, or uncontrolled pulmonary disease, including pulmonary fibrosis or acute lung disease.\n12. Known hypersensitivity to any study drug.\n13. Concurrent participation in another clinical study, unless observational (non-interventional) or in the follow-up phase of an interventional study.\n14. Any other condition deemed by the investigator to render the patient ineligible.",{"count":7,"type":22},[88],"This is a multicenter, open-label, prospective, single-arm, phase II study designed to evaluate the efficacy and safety of neoadjuvant zanidatamab combined with tislelizumab and chemotherapy, followed by selective bladder preservation, in patients with HER2-positive muscle-invasive bladder cancer (MIBC) staged cT2-4aN0-1M0.",[424],"Muscle Invasive Bladder Cancer (MIBC)","2025-12-08",{"date":427,"type":42},"2025-12-22",{"date":429,"type":42},"2025-10-25",{"date":431,"type":22},"2029-12",{"name":48,"class":49},12,{"id":435,"slug":436,"hasResults":12,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":238,"enrollmentInfo":441,"targetDuration":4,"studyType":23,"phases":443,"briefSummary":444,"conditions":445,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":454,"locationsCount":4},"100608204","early-phase-1-the-improvement-effect-of-henggliejin-on-fatty-liver-in-type-2-diabetes-patients-with-nonalcoholic-fatty-liver-100608204","NCT07198516","The Improvement Effect of Henggliejin on Fatty Liver in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver:","The Improvement Effect of Henggliejin on Fatty Liver in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver: a Multicenter, Prospective, Single Arm Clinical Study","Inclusion Criteria:\n\n* (1) Type 2 diabetes diagnosed according to WHO diagnostic criteria, age ≥ 18 years old, ≤ 70 years old, gender unlimited (2) Diagnosed with NAFLD according to the criteria of the \"Guidelines for the Prevention and Treatment of Non alcoholic Fatty Liver Disease (2018 Updated Edition)\" (3) Before screening, patients with type 2 diabetes who were treated with single or combined drugs of stable dose (except TZDs, SGLT2i, GLP-1RA, insulin and GKAs) for ≥ 8 weeks and had poor blood glucose control, 7% ≤ HbA1c ≤ 10% (4)BMI≥24 kg\u002Fm2 (5) Can understand the content and methods of this study and voluntarily sign an informed consent form\n\nExclusion Criteria:\n\n* (1) Patients with diabetes other than type 2 diabetes, including type 1 diabetes and gestational diabetes (2) Acute diabetes complications such as diabetes ketosis or ketoacidosis, diabetes hypertonic state, diabetes lactic acidosis or serious chronic diabetes complications (3) Individuals with a history of recurrent urinary tract infections and\u002For genital infections (as determined by clinical physicians) (4) Alcoholic liver disease (alcohol consumption equivalent to less than 30 g\u002Fd for males and less than 20 g\u002Fd for females in the past two years) (5) Exclude other liver diseases, such as chronic hepatitis B, chronic hepatitis C, primary cholestatic cirrhosis, ballistic obstructive diseases, drug-induced liver damage, hemochromatosis, hepatolenticular deformation, autoimmune hepatitis (6) Combined cirrhosis, combined liver cancer, HIV positive, drug abuse (7) Drugs (tamoxifen, amiodarone, sodium valproate, methotrexate, glucocorticoid, etc.), total parenteral nutrition, inflammatory bowel disease, celiac disease, hypothyroidism, Cushing's syndrome, β - lipoprotein deficiency, lipoatrophic diabetes, Mauriac syndrome, and other special conditions leading to fatty liver (8) Serious trauma or acute infection that may affect blood glucose control occurred within 4 weeks (9) Individuals who have experienced decompensated heart failure (NYHA grades III and IV), unstable angina, stroke or transient ischemic attack, myocardial infarction, severe arrhythmia, or have undergone cardiac surgery or vascular reconstruction (including coronary artery bypass grafting or percutaneous coronary intervention) within 6 months (10) There are obvious blood system diseases (such as aplastic anemia, myelodysplastic syndrome) or any diseases that cause hemolysis or red blood cell instability (such as malaria, hemolytic anemia) (11) Individuals with severe chronic gastrointestinal diseases, or those who have received treatment that may affect drug absorption (such as gastrointestinal surgery) (12) Uncontrolled hyperthyroidism (13) Individuals with mental or neurological disorders who are unwilling to communicate or unable to fully understand and collaborate (14) Pregnant or lactating women (15) There are any laboratory test indicators that meet the following standards:\n\n  1. Alanine aminotransferase\\>2.0 times ULN and\u002For aspartate aminotransferase\\>2.0 times ULN and\u002For total bilirubin\\>2.0 times ULN\n  2. Blood ketones\\>ULN\n  3. eGFR \\\u003C30ml\u002Fmin\u002F1.73 m2； Note: The formula for calculating eGFR is CKD-EPI (which can be calculated within the WeChat mini program)\n  4. Blood creatine kinase\\>3 times ULN (16) In addition to the above, the researchers have determined that patients who are not suitable to participate in this clinical trial",{"count":442,"type":22},149,[112],"To evaluate the effect and safety of Henggliejin on fatty liver in type 2 diabetes patients with nonalcoholic fatty liver disease",[446,447],"NAFLD","Diabete Type 2","2025-09-29",{"date":450,"type":42},"2025-09-30",{"date":452,"type":22},"2025-11-01",{"date":229,"type":22},{"name":48,"class":49},{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":461,"eligibilityCriteria":462,"healthyVolunteers":57,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":463,"targetDuration":4,"studyType":23,"phases":465,"briefSummary":466,"conditions":467,"keywords":470,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":479,"locationsCount":4},"100607600","a-prospective-randomized-double-blind-study-on-the-effects-of-different-anesthesia-strategies-on-postoperative-cough-in-patients-undergoing-video-assisted-thoracoscopic-surgery-100607600","NCT07190664","A Prospective, Randomized, Double-blind Study on the Effects of Different Anesthesia Strategies on Postoperative Cough in Patients Undergoing Video-assisted Thoracoscopic Surgery.","A Prospective, Randomized, Double-blind Study of Different Anesthesia Strategies for Postoperative Cough in Patients Undergoing Video-assisted Thoracoscopic Surgery","Chronic cough","Inclusion Criteria:\n\n1. planned wedge resection, segmentectomy or lobectomy;\n2. more than 18 years old;\n3. American Society of Anesthesiologists (ASA) grade ≤Ⅲ;\n4. body mass index (BMI) ≤24 kg\u002Fm2;\n5. Normal pulmonary function, predicted forced expiratory volume in 1 second (FEV1%) \\>50%, resting blood gas analysis showed arterial partial pressure of oxygen (PaO2) ≥75 mmHg and arterial partial pressure of carbon dioxide (PaCO2) \\\u003C45 MMHG;\n6. Normal cardiac function with ejection fraction (EF) \\> 50% of predicted value;\n7. Informed consent and signed informed consent form.\n\nExclusion Criteria:\n\n* (1) patients who refuse surgery and\u002For anesthesia; (2) preoperative pulmonary infection; (3) previous history of ipsilateral surgery or other medical history that may cause extensive pleural adhesions; (4) phrenic nerve palsy on the non-operative side; (5) patients with high risk of preoperative reflux (fasting \\\u003C6 hours) or gastroesophageal reflux disease; (6) patients with heart, kidney, liver and other organ dysfunction and surgical contraindications; (7) with severe cognitive, psychological and communication disorders.",{"count":464,"type":22},228,[25],"This study aims to systematically evaluate the effects of different anesthesia methods on postoperative chronic cough in lung cancer patients undergoing video-assisted thoracoscopic lung resection (VATS), and to clarify the effectiveness and safety of each anesthesia airway management strategy in reducing the incidence of postoperative chronic cough, shortening the duration of cough, alleviating the severity of symptoms, and improving the postoperative quality of life of patients.",[468,469],"Chronic Cough","Video-assisted Thoracoscopic Surgery (VATS)",[471,472],"Video-assisted thoracoscopic surgery","chronic cough","2025-09-17",{"date":475,"type":42},"2025-09-24",{"date":477,"type":22},"2025-10-01",{"date":410,"type":22},{"name":48,"class":49},{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":282,"enrollmentInfo":488,"targetDuration":4,"studyType":23,"phases":489,"briefSummary":490,"conditions":491,"keywords":493,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":506,"locationsCount":50},"100562295","phase-2-biomarker-based-neoadjuvant-strategies-for-locally-advanced-resectable-escc-100562295","NCT06601309","Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC","Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma: an Exploratory Phase II Single-arm Clinical Study","ESCC","Inclusion Criteria:\n\n1. Diagnosis: Histologically confirmed esophageal squamous cell carcinoma (ESCC).\n2. Stage: Resectable locally advanced ESCC (clinical stage II-III according to the AJCC\u002FUICC 8th edition).\n3. Age: 18-75 years old.\n4. Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n5. PD-L1 Expression: Available PD-L1 expression level (CPS).\n6. Surgical Eligibility: Assessed as eligible for surgical resection by a thoracic surgeon.\n7. Laboratory Requirements:\n\n   * Adequate bone marrow function: Absolute neutrophil count (ANC) ≥ 1.5 x 10\\^9\u002FL, Platelets ≥ 100 x 10\\^9\u002FL, Hemoglobin ≥ 9 g\u002FdL.\n   * Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN), AST and ALT ≤ 2.5 x ULN.\n   * Adequate renal function: Serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 60 mL\u002Fmin.\n8. Informed Consent: Ability to understand and willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Distant Metastasis: Presence of distant metastasis.\n2. Other Malignancies: History of other malignancies within the past 5 years, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin carcinoma, or other localized non-invasive malignancy.\n3. Autoimmune Diseases: History of active autoimmune diseases requiring systemic treatment within the past 2 years.\n4. Infections: Active infection requiring systemic therapy.\n5. Uncontrolled Conditions: Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n6. Previous Treatment: Previous treatment with anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies.\n7. Pregnancy and Lactation: Pregnant or breastfeeding women. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to randomization.\n8. Allergies: Known allergy or hypersensitivity to study drugs or any excipient of these medications.",{"count":240,"type":22},[88],"This study aims to evaluate the impact of the neoadjuvant treatment strategy based on CPS score on the pathological complete response (pCR) rate in patients with resectable locally advanced esophageal cancer.",[492],"Esophageal Squamous Cell Carcinoma",[289,494,495,496,497,498],"Neoadjuvant Therapy","Pathological Complete Response (pCR)","Immunotherapy","Chemoradiotherapy","Biomarkers","2025-09-08",{"date":501,"type":42},"2025-09-15",{"date":503,"type":42},"2024-07-11",{"date":505,"type":22},"2026-12-01",{"name":48,"class":49},{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":512,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":513,"targetDuration":515,"studyType":62,"phases":4,"briefSummary":516,"conditions":517,"keywords":518,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":526,"locationsCount":50},"100605531","leptin-a-marker-for-aml-chemo-sensitivity-100605531","NCT07163728","Leptin: A Marker for AML Chemo-Sensitivity","Bone Marrow Supernatant Leptin as A Predictor of Chemotherapy Sensitivity in AML Patients",{"count":514,"type":22},86,"1 Month","Acute Myeloid Leukemia (AML) is a malignant clonal disorder of hematopoietic stem\u002Fprogenitor cells, with a five-year survival rate of approximately 30%. Chemotherapy resistance and relapse remain major challenges. Increased bone marrow adipocytes contribute to AML cell drug resistance.This study found that elevated levels of the adipokine leptin enhance oxidative phosphorylation (OXPHOS) in AML cells, accompanied by increased mitochondrial reactive oxygen species (mtROS), which stimulates antioxidant capacity and thereby induces chemotherapy resistance. By establishing a correlation between leptin levels in bone marrow supernatant and clinical outcomes in AML patients, this research provides novel strategic insights for targeting drug resistance and improving prognostic evaluation.",[185,186],[185,191,519],"Chemotherapy sensitivity","2025-09-02",{"date":522,"type":42},"2025-09-09",{"date":524,"type":42},"2025-08-01",{"date":229,"type":22},{"name":48,"class":49},{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":4,"eligibilityCriteria":533,"healthyVolunteers":12,"sex":108,"minAge":19,"maxAge":282,"enrollmentInfo":534,"targetDuration":4,"studyType":23,"phases":536,"briefSummary":537,"conditions":538,"keywords":541,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":50},"100493362","phase-2-pirfenidonevsplacebo-as-prophylaxis-against-acute-radiation-induced-lung-injury-following-hfrt-in-breast-cancer-patients-100493362","NCT05704166","PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients","Pirfenidone Versus Placebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following Hypofractionated Radiotherapy in Breast Cancer Patients (PRILI): A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating","Inclusion Criteria:\n\n* To be enrolled in this study, patients must meet all of the following inclusion criteria:\n\n  1. Breast invasive carcinoma or ductal carcinoma in situ or lobular carcinoma in situ confirmed by histology;\n  2. Age 18-75, female;\n  3. The physical state score of the Eastern Tumor Cooperative Group (ECOG) was 0-2;\n  4. Patients meeting the indications of postoperative radiotherapy and neoadjuvant chemotherapy: clinical stage 3 or above or postoperative ypT3-T4 or N+; Non-neoadjuvant chemotherapy patients: postoperative pathological staging of pT3-T4 or pN2 or above, or positive for upper and lower clavicle and lymph nodes in the internal milk region, or positive for clinical consideration; For patients with pT1-2N1, postoperative adjuvant radiotherapy should be determined based on the patient's age, tumor grade, incisal margin, number of positive lymph nodes, molecular typing, past complications, and patient's intention.\n  5. Radiotherapy regimen was chest wall + supraclavicular 40Gy\u002F15f after root modification, or whole milk ± upper and lower clavicular 40Gy\u002F15f after breast preservation, tumor bed simultaneous supplement 50Gy\u002F15f;\n  6. All screening period laboratory tests should be performed in accordance with protocol requirements and within 28 days prior to enrollment. The values of laboratory tests performed by screening must meet the following criteria:\n\n     blood routine check all meet the following criteria: A. Hb≥90g\u002FL; B. ANC≥1.5×109\u002FL; C. PLT≥70×109\u002FL; biochemical examination all meet the following criteria: TBIL \\\u003C 1.5× upper limit of normal range (ULN); ALT and AST≤2.5 x ULN; Serum Cr≤1.25×ULN or endogenous creatinine clearance ≥45 mL\u002Fmin (Cockcroft-Gault formula)\n  7. Women who are at risk of becoming pregnant must undergo a negative serum pregnancy test within 7 days before the first dose and be willing to use a highly effective method of contraception during the trial period and 120 days after the last dose of the test drug. Male subjects with a partner of a woman of reproductive age should be surgically sterilized or consent to a highly effective method of contraception during the trial period and 120 days after the last test drug administration;\n  8. The subjects voluntarily joined the study, signed the informed consent, had good compliance, and cooperated with follow-up.\n\nExclusion Criteria:\n\n* Patients with any of the following criteria were not enrolled in this study\n\n  1. History and complications A. male breast cancer patients; B. Did not meet the conditions of large segmentation radiotherapy (upper and lower clavicular lymph node metastasis, internal milk lymph node metastasis, the patient refused large segmentation radiotherapy); C. The subject has any active, known, or suspected autoimmune disease. To admit subjects who are in a stable state and do not require systemic immunosuppressive therapy; D. The patient is participating in another clinical study or less than 4 weeks after the end of the previous clinical study; E. Patients with a known or highly suspected history of interstitial pneumonia; Or may interfere with the detection or management of suspected drug-related pulmonary toxicity; F. A history of other malignant tumors; Except in patients who have had potentially curable therapy and have not had disease recurrence for 5 years since treatment began; G. Pregnant women and patients with mental illness; H. Prior treatment with radiotherapy, chemotherapy, etc.; I. Patients with active tuberculosis should be excluded; J. Severe acute or chronic lung infections requiring systemic treatment; K. Patients with obvious blood coughing or daily hemoptysis of half a teaspoon (2.5ml) or more in the 2 months before randomization; L. Patients with heart failure (New York Heart Association standard Class III or IV), poor coronary artery disease control or arrhythmia, or a history of myocardial infarction in the 6 months prior to screening despite receiving appropriate medication.\n  2. Physical examination and laboratory examination A. A known history of testing positive for human immunodeficiency virus (HIV) or a known history of acquired immunodeficiency syndrome (AIDS); B. untreated active hepatitis (hepatitis B: HBsAg positive with HBV DNA≥ 500 IU\u002FmL; Hepatitis C: HCV RNA positive and abnormal liver function); Combined with hepatitis B and hepatitis C co-infection.\n  3. As determined by the investigator, the patient may have other factors that may lead to the termination of the study, such as other serious diseases or serious abnormalities in laboratory tests or other factors that may affect the safety of the subjects, or family or social factors such as the collection of test data and samples.",{"count":535,"type":22},214,[88],"The incidence of chest CT manifestations of lung injury after radiotherapy for breast cancer is more than 50%. Although the prognosis and quality of life of patients are rarely affected, it is still necessary to prevent the occurrence of minor radiation lung injury with the use of more novel drugs and subsequent salvage treatment may aggravate the radiation injury. This study intends to conduct a randomized, double-blind, single-center clinical study of pirfenidone versus placebo in the prevention of acute radiation induced lung injury after breast cancer surgery",[539,540],"Acute Lung Injury","Prevention",[542,543,544,545],"Pirfenidone","Prophylaxis","Acute Radiation-induced Lung Injury","Breast Cancer","2025-08-04",{"date":548,"type":42},"2025-08-08",{"date":550,"type":42},"2023-03-16",{"date":552,"type":22},"2026-05-31",{"name":48,"class":49},{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":4,"eligibilityCriteria":560,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":355,"enrollmentInfo":561,"targetDuration":562,"studyType":62,"phases":4,"briefSummary":563,"conditions":564,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":573,"locationsCount":50},"100599584","different-methods-of-aerosolized-polymyxin-b-inhalation-for-treating-carbapenem-resistant-gram-negative-bacterial-pneumonia-100599584","NCT07086391","Different Methods of Aerosolized Polymyxin B Inhalation for Treating Carbapenem-Resistant Gram-Negative Bacterial Pneumonia.","A Prospective Clinical Study on Different Methods of Aerosolized Polymyxin B Inhalation for the Treatment of Carbapenem-Resistant Gram-Negative Bacterial Pneumonia","Inclusion Criteria:\n\n* Pneumonia diagnosed per Chinese Thoracic Society criteria (radiographic + clinical evidence).\n* Sputum culture-confirmed carbapenem-resistant Gram-negative bacteria susceptible to polymyxin B.\n* ≥3 days of aerosolized polymyxin B therapy.\n* Mechanically ventilated with an artificial airway.\n\nExclusion Criteria:\n\n* Polymyxin B aerosol use planned for \\\u003C3 days.\n* Terminal status (life expectancy \\\u003C48h).\n* Severe liver\u002Fkidney dysfunction (ALT\u002FAST \\>5× ULN; eGFR \\\u003C30 mL\u002Fmin).\n* No informed consent.",{"count":284,"type":22},"28 Days","Study Design:\n\nA randomized, open-label, parallel-group clinical trial comparing the efficacy and safety of jet nebulization versus vibrating mesh nebulization of sulfate polymyxin B in mechanically ventilated patients with carbapenem-resistant Gram-negative bacterial pneumonia.\n\nParticipants:\n\n144 patients (72 per group) will be enrolled from December 2023 to December 2025.\n\nInterventions:\n\nGroup A: 25mg polymyxin B + 5ml sterile water via jet nebulizer (respirator-assisted).\n\nGroup B: 25mg polymyxin B + 5ml sterile water via vibrating mesh nebulizer (respirator-assisted).\n\nBoth groups receive additional intravenous polymyxin B (2.0mg\u002Fkg loading dose, followed by 1.25mg\u002Fkg every 12h) starting 12h after nebulization.\n\nTreatment duration: 14 days.\n\nKey Procedures:\n\nNebulization parameters: Fixed ventilator settings (SIMV+PSV mode, tidal volume 8ml\u002Fkg, PEEP 6cmH₂O).\n\nBronchoalveolar lavage (BAL) and blood sampling:\n\nBAL fluid (BALF) and blood collected pre-nebulization (baseline), 1h post-nebulization, and at steady-state (days 3-7).\n\nBALF analyzed for polymyxin B concentration, urea nitrogen, and inflammatory mediators (IL-6, TNF-α, etc.).\n\nPrimary Outcomes:\n\nClinical efficacy:\n\nTotal response rate (cure + improvement). 28-day survival rate. Time to fever resolution and bacterial clearance.\n\nDrug exposure:\n\nPolymyxin B concentration in alveolar epithelial lining fluid (ELF) and blood.\n\nSecondary Outcomes:\n\nInflammatory response: Changes in BALF and serum IL-6, TNF-α, CRP levels.\n\nSafety:\n\nNephrotoxicity (changes in serum creatinine\u002Furea nitrogen). Airway complications (bronchospasm incidence).\n\nAssessment Timeline:\n\nClinical monitoring: Daily evaluation of vital signs, sputum volume, and ventilator parameters.\n\nLab tests: Blood tests (hematology, renal function, inflammatory markers) at baseline, days 3\u002F7\u002F14.\n\nMicrobiological evaluation: Sputum cultures on days 3\u002F7\u002F14.\n\nStatistical Analysis:\n\nEfficacy and safety endpoints compared between groups using t-tests or chi-square tests.\n\nA p-value \\\u003C0.05 will be considered statistically significant.",[565,566],"Carbapenem-Resistant Enterobacteriaceae Infection","Pneumonia - Bacterial","2025-07-18",{"date":569,"type":42},"2025-07-25",{"date":571,"type":42},"2023-02-01",{"date":319,"type":22},{"name":48,"class":49},{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":578,"acronym":4,"eligibilityCriteria":579,"healthyVolunteers":57,"sex":18,"minAge":19,"maxAge":83,"enrollmentInfo":580,"targetDuration":4,"studyType":23,"phases":582,"briefSummary":583,"conditions":584,"keywords":586,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":589,"lastUpdatePostDateStruct":590,"startDateStruct":592,"completionDateStruct":593,"leadSponsor":594,"locationsCount":50},"100533128","stem-cell-derived-exosomes-in-the-treatment-of-melasma-and-its-percutaneous-penetration-100533128","NCT06221787","Stem Cell Derived Exosomes in the Treatment of Melasma and Its Percutaneous Penetration","Inclusion Criteria:\n\n\\- Patients diagnosed with chloasma who meet the clinical diagnostic standards and efficacy standards (revised version) of chloasma and have skin lesions on the face.\n\nIt is hoped that exosomes combined with 1565 non-ablative fractional laser, blue aurora or micro-needle can improve facial chloasma.\n\nFully understand and understand the content and significance of this study, implementation plan, possible benefits, risks and countermeasures, rights and obligations of subjects (including privacy protection, free withdrawal), willing to participate in this clinical study and able to cooperate well, Those who signed the informed consent form.\n\nExclude post-inflammatory pigmentation, malar brown-green nevus, Riehl's melanosis, pigmented lichen planus and other skin diseases.\n\nSubjects who agree not to use other cosmetic treatments related to the study during the study period.\n\nExclusion Criteria:\n\n1. Patients who refuse to sign the informed consent form to participate in the trial;\n2. Those with a history of important organ diseases, or a history of autoimmune diseases or immune dysfunction;\n3. Abnormal coagulation function, current use of anticoagulants, thrombophilia and history of familial genetic diseases;\n4. Pregnant or lactating women;\n5. Patients taking oral contraceptives or hormone replacement therapy during the study period or within the past 12 months;\n6. Patients with scar constitution;\n7. Active skin infection;\n8. Those who have a history of multiple severe allergies, a history of hereditary allergies, photosensitivity or photosensitivity drugs, such as sulfa drugs and tetracyclines, those who are allergic to local anesthetics and those who are allergic to lidocaine components, and those who plan to undergo detoxification during the study Allergy healer;\n9. History of post-inflammatory pigmentation;\n10. Those who have received treatment for chloasma in the past;\n11. Those who have undergone chemical peeling, dermabrasion or other skin resurfacing on their face in the past;\n12. Patients who are participating in other clinical studies;\n13. Other reasons that the researcher considers unsuitable for clinical investigators.",{"count":581,"type":22},80,[25],"Melasma is a refractory skin disease due to its complex pathogenesis and difficult treatment. Studies have found that human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-Exos) could serve as a novel cell-free therapeutic strategy in regenerative and aesthetic medicine. It could potentially treat melasma, but the skin barrier is a challenge. This study aims to explore the safety and efficacy of hUCMSC-Exos in the treatment of melasma and means to promote its percutaneous penetration.",[585],"Melasma",[585,587,588],"Stem cell-derived exosomes","Percutaneous Penetration","2025-06-29",{"date":591,"type":42},"2025-07-02",{"date":227,"type":42},{"date":69,"type":22},{"name":48,"class":49},{"id":596,"slug":597,"hasResults":12,"nctId":598,"briefTitle":599,"officialTitle":599,"acronym":4,"eligibilityCriteria":600,"healthyVolunteers":57,"sex":18,"minAge":19,"maxAge":83,"enrollmentInfo":601,"targetDuration":4,"studyType":23,"phases":603,"briefSummary":604,"conditions":605,"keywords":608,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":589,"lastUpdatePostDateStruct":611,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":50},"100514909","umbilical-cord-stem-cells-for-skin-grafts-in-donor-site-wounds-100514909","NCT05984628","Umbilical Cord Stem Cells for Skin Grafts in Donor Site Wounds","Inclusion Criteria:\n\n1. Patients between 18 and 60 years old with extensive scars, large benign tumors, or fresh wounds on the body surface.\n2. Patients who undergo medium-thickness skin graft surgery (donor site can be from the thigh, abdomen, or back).\n3. Participants who have a thorough understanding of the study objectives, significance, implementation plan, potential benefits, risks involved, measures to address risks, and the rights and obligations of the subjects (including privacy protection and the right to withdraw), and are willing to participate in this clinical study and can cooperate effectively.\n\nExclusion Criteria:\n\nParticipants who meet any of the following criteria are not suitable for inclusion:\n\n1. Hypertension, hypotension, heart disease (including history of myocardial ischemia, coronary heart disease, myocarditis).\n2. Liver or kidney dysfunction.\n3. Infectious diseases (including viral hepatitis, syphilis, HIV\u002FAIDS, etc.).\n4. Venous thrombosis, thoracic or abdominal aortic aneurysm, aortic dissection.\n5. Blood disorders (abnormal coagulation function, anemia, leukemia, polycythemia vera, aplastic anemia, etc.).\n6. Allergic conditions (urticaria, bronchial asthma, history of allergic reactions to two or more drugs or foods).\n7. Respiratory system diseases (chronic bronchitis, emphysema, bronchiectasis, respiratory failure, chronic obstructive pulmonary disease, interstitial pneumonia).\n8. Digestive system diseases (severe gastric or duodenal ulcers, chronic gastritis, chronic pancreatitis).\n9. Urinary system diseases (chronic urinary tract infections, nephritis, nephrotic syndrome).\n10. Endocrine system diseases (hyperthyroidism, diabetes, acromegaly, pituitary diseases, adrenal diseases, diabetes insipidus).\n11. Organic neurological disorders or psychiatric illnesses (encephalitis, sequelae of traumatic brain injury, epilepsy, schizophrenia, hysteria, depression, severe insomnia, neurasthenia).\n12. Chronic skin diseases (especially infectious, allergic, and inflammatory systemic skin diseases, such as extensive eczema, pemphigus, pemphigoid).\n13. Autoimmune diseases and collagen diseases (such as systemic lupus erythematosus, dermatomyositis, scleroderma).\n14. History of long-term smoking, alcohol abuse, or drug addiction.\n15. History of major surgeries (such as gastric, lung, splenic, renal, or liver resection).\n16. History of other significant malignant tumors.\n17. Blood donation or organ transplantation within the past 5 years.\n18. Pregnancy, lactation, menstrual period, or within 1 year after termination of pregnancy.\n19. Previous circumstances of being rejected for voluntary blood donation.\n20. Other situations deemed unsuitable for participation in this study by the investigators.",{"count":602,"type":22},88,[25],"The goal of this clinical trial is to evaluate the safety and effectiveness of human umbilical cord mesenchymal stem cell (hUCMSC) therapy in patients undergoing medium-thickness skin grafts for donor site wounds. The study aims to answer the following main questions:\n\n* Question 1: Does hUCMSC therapy improve the healing quality and speed of donor site wounds in comparison to standard treatment?\n* Question 2: Does hUCMSC therapy reduce scar formation in the donor site wounds?\n\nParticipants in this study will undergo medium-thickness skin grafts, and those in the treatment group will receive hUCMSC therapy. The main tasks for participants will involve regular follow-up visits, monitoring of wound healing progress, and assessment of any potential side effects or complications associated with the therapy.\n\nIn order to evaluate the effectiveness of hUCMSC therapy, researchers will compare the treatment group receiving hUCMSC therapy with a control group that receives standard treatment alone. The aim is to determine if the use of hUCMSC therapy leads to improved healing outcomes and reduced scar formation compared to the standard treatment group.",[606,607],"Skin Wound","Scar, Hypertrophic",[609,606,607,610],"hUCMSC","Stem cell",{"date":591,"type":42},{"date":613,"type":42},"2021-10-20",{"date":615,"type":22},"2026-10-20",{"name":48,"class":49},""]